Ratings by Cantor Fitzgerald (Pete Stavropoulos)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/2/2026 | Definium Therapeutics Inc | DFTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/16/2026 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/14/2026 | Annexon Biosciences | ANNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/14/2026 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/14/2026 | MindMed | MNMD | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/13/2026 | atai Life Sciences N.V | ATAI | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/13/2026 | Novavax | NVAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/12/2026 | Stoke Therapeutics | STOK | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/5/2026 | Stoke Therapeutics | STOK | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/11/2025 | Rezolute | RZLT | Downgrade | Neutral (Overweight) |
10.94 (3.11) |
-71.57% | Details | |
| 12/1/2025 | Bright Minds Biosciences Inc. | DRUG | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/26/2025 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/24/2025 | Novavax | NVAX | New Coverage | Overweight (N/A) |
8.36 (9.98) |
19.38% | Details | |
| 10/22/2025 | Alector Inc. | ALEC | Downgrade | Neutral (Overweight) |
3.31 (2.00) |
-39.58% | Details | |
| 10/15/2025 | Cybin Inc. | CYBN | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/13/2025 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/22/2025 | Dianthus Therapeutics | DNTH | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/24/2025 | Rezolute | RZLT | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/10/2025 | Eledon Pharamceuticals | ELDN | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/7/2025 | Jasper Therapeutics | JSPR | Downgrade | Neutral (Overweight) |
6.77 (1.38) |
-79.62% | Details | |
| 7/1/2025 | Arcturus Therapeutics | ARCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/26/2025 | Eledon Pharamceuticals | ELDN | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/29/2025 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/23/2025 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/15/2025 | Eledon Pharamceuticals | ELDN | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2025 | Annexon Biosciences | ANNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2025 | Arcturus Therapeutics | ARCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/4/2025 | Pliant Therapeutics | PLRX | New Coverage | Neutral (N/A) |
3.44 (1.33) |
-61.34% | Details | |
| 3/3/2025 | Jasper Therapeutics | JSPR | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/18/2025 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/10/2025 | Voyager Therapeutics | VYGR | New Coverage | Overweight (N/A) |
5.73 (3.90) |
-31.94% | Details | |
| 6/27/2024 | Dianthus Therapeutics | DNTH | New Coverage | Overweight (N/A) |
23.69 (65.20) |
175.22% | Details | |
| 1/8/2024 | Vera Therapeutics | VERA | New Coverage | Overweight (N/A) |
15.53 (39.07) |
151.58% | Details | |
| 8/8/2023 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/28/2023 | Rezolute | RZLT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/18/2023 | Acumen Pharmaceuticals, Inc. | ABOS | New Coverage | Overweight (N/A) |
5.45 (3.31) |
-39.27% | Details | |
| 5/1/2023 | Pliant Therapeutics | PLRX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/28/2023 | Orchard Therapeutics | ORTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/14/2023 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2023 | Eledon Pharamceuticals | ELDN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2023 | Jasper Therapeutics | JSPR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2022 | Arcturus Therapeutics | ARCT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/19/2022 | Arcturus Therapeutics | ARCT | New Coverage | Overweight (N/A) |
15.86 (7.11) |
-55.17% | Details | |
| 7/11/2022 | Pliant Therapeutics | PLRX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/15/2022 | Rezolute | RZLT | New Coverage | Overweight (N/A) |
3.03 (10.94) |
261.06% | Details | |
| 5/25/2022 | Pliant Therapeutics | PLRX | New Coverage | Overweight (N/A) |
4.93 (3.44) |
-30.22% | Details | |
| 5/13/2022 | Eledon Pharamceuticals | ELDN | New Coverage | Overweight (N/A) |
2.41 (2.78) |
15.35% | Details | |
| 2/28/2022 | Jasper Therapeutics | JSPR | New Coverage | Overweight (N/A) |
3.74 (1.38) |
-63.1% | Details | |
| 12/29/2021 | Orchard Therapeutics | ORTX | New Coverage | Overweight (N/A) |
1.19 (16.70) |
1303.36% | Details | |
| 9/23/2021 | Annexon Biosciences | ANNX | New Coverage | Overweight (N/A) |
21.12 (5.16) |
-75.57% | Details |
